Skip to content

Amgen AMGN Price / earnings

Price / earnings at other companies

Eli Lilly logo
Eli LillyLLY
32.5×-34.3×
Pfizer logo
PfizerPFE
14.7×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
18.5×+3.1×
Roivant Sciences logo
Roivant SciencesROIV
249.7×+248×
Merck & Co. logo
Merck & Co.MRK
33.3×+20.3×
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
17×-6.2×

Other financials

Income statement

See full
Revenue$8.6B+5.8%
Gross profit$5.9B+13.4%
Operating income$2.7B+126%
Net income$1.8B+5.1%
EPS (diluted)$3.34+4.4%

Balance sheet

See full
Cash & equivalents$559.0M+10.0%
Total debt$57.3B-0.1%
Total equity$9.2B+48.1%
Total assets$92.5B+3.5%

Cash flow

See full
Operating cash flow$2.2B+57.4%
CapEx$712.0M+73.2%
Free cash flow$1.5B+50.7%

Valuation

See full
Market cap$184.4B+13.3%
Enterprise value$241.16B+9.9%
P/S+0.2×

Profitability

See full
Gross margin68.3%+5.3pp
Operating margin28.4%+6.6pp
Net margin21%+3.6pp

Returns & leverage

See full
Return on equity101.3%-4.4pp
Debt / equity6.2×-3.0×
Current ratio1.3×+0.1×

Where this comes from

Calculated from Amgen’s reported figures.

Based on the most recent quarter.

The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amgen's price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amgen's price / earnings?
Amgen (AMGN) reported price / earnings of 24.3× in Q1 2026.
How has Amgen's price / earnings changed year-over-year?
Amgen's price / earnings decreased by 13.8% year-over-year, from 28.2× to 24.3×.
What is the long-term trend for Amgen's price / earnings?
Over 4 years (2021 to 2025), Amgen's price / earnings has grown at a 2.4% compound annual growth rate (CAGR), from 86.5× to 95.3×.
What does price / earnings mean?
How many dollars investors pay for each dollar of the company's annual profit.
How do you interpret price / earnings?
Lower can mean cheaper — or that the market expects earnings to fall. High multiples embed growth expectations. Meaningless when earnings are negative, so it is suppressed there.
How does price / earnings compare across companies?
Compare against the company's own history and sector peers, not across sectors with different growth and risk profiles.